Papulopustular Rosacea
37
2
2
28
Key Insights
Highlights
Success Rate
93% trial completion (above average)
Published Results
20 trials with published results (54%)
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 5/100
5.4%
2 terminated out of 37 trials
93.3%
+6.7% vs benchmark
38%
14 trials in Phase 3/4
71%
20 of 28 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 28 completed trials
Clinical Trials (37)
A Phase 2 Study to Investigate the Efficacy, Safety and Tolerability of Remibrutinib (LOU064) in Adult Patients With Papulopustular Rosacea (PPR)
PDE4 Inhibition in Seborrheic Dermatitis and Papulopustular Rosacea
Study to Evaluate the Safety of ATR-04
Efficacy and Safety of Topical Clascoterone (WINLEVI) Cream 1% in Patients With Facial Acneiform Rosacea
Deucravacitinib Rosacea
A Safety and Efficacy Study to Evaluate Rosacea
A Randomized, Double-Blind Study to Assess the Safety, Efficacy and Tolerability of Oral DFD-29 Capsules for the Treatment of Rosacea.
A Study to Assess the Safety, Efficacy and Tolerability of Oral DFD-29 Capsules for the Treatment of Rosacea (MVOR-2)
Safety, Efficacy and Pharmacokinetics of Rifaximin in Patients With Moderate-to-severe Papulopustular Rosacea
Study of TP-04 in Participants With Papulopustular Rosacea
Safety and Efficacy of Azelaic Acid Foam, 15 % in Papulopustular Rosacea
A Multicenter Trial of a Topical Medication for Papulopustular Rosacea Applied Twice Daily Versus Once Daily
Safety and Pharmacokinetics of Azelaic Acid Foam, 15% in Papulopustular Rosacea
Evaluation of Topical Encapsulated Benzoyl Peroxide on the Skin Microbiome and Skin Biophysical Properties
Excel V 532 nm KTP Laser for Treatment of Erythematotelangiectatic Rosacea & Papulopustular Rosacea
Photodynamic Therapy for Papulopustular Rosacea
Patient Centered Outcomes in Rosacea: An Exploratory Multi-media Analysis of the Patient Experience on Oracea
A Study to Evaluate the Long-Term Safety of Topical Administration of FMX103 in the Treatment of Moderate to Severe Papulopustular Rosacea
A Study of S5G4T-1 in the Treatment of Papularpustular Rosacea
A Long-Term Safety Study of S5G4T-1 in the Treatment of Papulopustular Rosacea